The burgeoning UK landscape surrounding psychedelics is increasingly nuanced, demanding careful navigation. While therapeutic investigation into compounds like psilocybin and copyright continues to progress, and patient access via private clinics is increasing, the policy framework remains unclear. This presents a distinctive situation for both see